CompanyGraphWhat stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionGross margin is 24.2%, lower than 95% of its Medical Devices peers (median 61%)
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.45%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
4.3%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
6.15BCNY913.50M · vs all stocks (USD)
Trailing P/E
38.63xvs Medical Devices peers
Revenue (TTM)
2.40BCNY355.92M · vs all stocks (USD)
Profit Margin
5.40%vs Medical Devices peers
Beta
1.14xvs all stocks
52-Week Change
30.03%vs all stocks
Market Capitalization
6.15BCNY913.50M · vs all stocks (USD)
Enterprise Value
5.26BCNY780.83M · vs all stocks (USD)
Trailing P/E
38.63xvs Medical Devices peers
Price to Sales (TTM)
2.58xvs Medical Devices peers
Price to Book (MRQ)
2.43xvs Medical Devices peers
Enterprise to Revenue
2.19xvs Medical Devices peers
Enterprise to EBITDA
16.85xvs Medical Devices peers
Gross Margin
24.20%vs Medical Devices peers
Profit Margin
5.40%vs Medical Devices peers
Operating Margin
-1.93%vs Medical Devices peers
Return on Assets (TTM)
2.99%vs Medical Devices peers
Return on Equity (TTM)
7.09%vs Medical Devices peers
Revenue (TTM)
2.40BCNY355.92M · vs all stocks (USD)
Revenue per Share (TTM)
23.08CNYUpdated Aug 20, 2026Quarterly Revenue Growth
37.30%vs Medical Devices peers
Gross Profit (TTM)
775.99MCNY115.25M · vs all stocks (USD)
EBITDA (TTM)
313.95MCNY46.63M · vs all stocks (USD)
Net Income (TTM)
129.34MCNY19.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-35.46%vs Medical Devices peers
Operating Cash Flow (TTM)
-148.84MCNY-22.11M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-302.75MCNY-44.96M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.45%vs all stocks
Payout Ratio
4.35%vs Medical Devices peers
Minority Interest (Equity)
22.35MCNYFY2025 · Dec 31, 2025Revenue
2.29BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.54BCNYFY2025 · Dec 31, 2025Gross Profit
750.50MCNYFY2025 · Dec 31, 2025Operating Income
272.19MCNY40.42M · vs all stocks (USD)
Pre-tax Income
141.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
21.30MCNYFY2025 · Dec 31, 2025Net Income
120.35MCNYFY2025 · Dec 31, 2025EBIT
182.66MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
313.95MCNYFY2025 · Dec 31, 2025Research & Development
79.88MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
141.24MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.14CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.04CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
103.37MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
103.37MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
120.35MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.50MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-572.29MCNYFY2025 · Dec 31, 2025Free Cash Flow
-630.73MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
473.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
120.35MCNYFY2025 · Dec 31, 2025Other Non-cash Items
44.01MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-499.50MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-237.16MCNYFY2025 · Dec 31, 2025Capital Expenditures
-58.43MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.00MCNYFY2025 · Dec 31, 2025Sale of Investments
40.50MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-27.93MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
383.40MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-654.08MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-19.32MCNYFY2025 · Dec 31, 2025Other Financing Charges
-57.53MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-347.53MCNYFY2025 · Dec 31, 2025Shares Outstanding
107.78MSharesUpdated Aug 20, 2026Float Shares
50.42MSharesUpdated Aug 20, 2026% Held by Insiders
38.54%vs all stocks
% Held by Institutions
2.69%vs all stocks
Total Cash (MRQ)
402.89MCNY59.84M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.86CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.03BCNY152.57M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5327xvs Medical Devices peers
Current Ratio (MRQ)
2.23xvs Medical Devices peers
Book Value per Share (MRQ)
18.26CNYUpdated Aug 20, 2026Total Assets
4.30BCNY638.12M · vs all stocks (USD)
Total Current Assets
3.43BCNYFY2025 · Dec 31, 2025Total Liabilities
2.36BCNYFY2025 · Dec 31, 2025Total Non-current Assets
870.92MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
891.24MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.47BCNYFY2025 · Dec 31, 2025Cash
476.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
46.87MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
522.89MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.88BCNYFY2025 · Dec 31, 2025Inventory
717.48MCNYFY2025 · Dec 31, 2025Accounts Payable
697.64MCNYFY2025 · Dec 31, 2025Short-term Debt
40.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
94.41MCNYFY2025 · Dec 31, 2025Long-term Debt
848.62MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
15.99MCNYFY2025 · Dec 31, 2025Common Stock (Book)
107.77MCNYFY2025 · Dec 31, 2025Retained Earnings
484.13MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.93BCNY287.22M · vs all stocks (USD)
Treasury Stock
70.00MCNYFY2025 · Dec 31, 202552-Week Low
28.61CNYUpdated Aug 20, 202652-Week High
81.82CNYUpdated Aug 20, 202652-Week Change
30.03%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
53.12CNYUpdated Aug 20, 2026200-Day MA
49.02CNYUpdated Aug 20, 2026Avg 10-Day Volume
14.70MSharesUpdated Aug 20, 2026Avg 30-Day Volume
10.98MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.15CNYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 24.2%, lower than 95% of its Medical Devices peers (median 61%)Significant
Gross margin: 0.24Industry median: 0.61Industry P5: 0.28Peers compared: 102
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 19,209,905.92Operating Cash Flow (USD, TTM): -22,105,448.276
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -3.86
Altman Z-Score 2.94: safe zoneNotable
Altman Z-Score: 2.94
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Moura Dubeux Engenharia S.A.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing
Krishana Phoschem Ltd.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing
Coforge Limited
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthReceivables Heavy and Growing